October 15 – 18, 2020
Abstract Submission DeadlineTuesday, July 14, 2020, 11:59 p.m. ET
Advance Registration DeadlineMonday, August 31, 2020, 11:59 p.m. ET
Chi Van Dang, Ludwig Institute for Cancer Research, New York, New York
Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, Massachusetts
Craig B. Thompson, Memorial Sloan-Kettering Cancer Center, New York, New York
Matthew G. Vander Heiden, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts
Interest in cancer metabolism continues to grow due to our deeper mechanistic understanding of the interconnected signaling cascades, the identification of mutated genes and metabolic enzymes involved, and the metabolic perturbation hallmarks of cancer favoring tumor progression. Cancer genome sequencing efforts have revealed that genes involved in chromatin remodeling and epigenetic regulation are frequently and specifically mutated in a wide variety of cancers. Moreover, data has shown us that cell metabolism impacts gene expression through epigenetic modifications. Increase in the research that focuses on epigenetics and metabolism illuminate how far we have come in identifying newly recognized mechanisms central to the genesis of cancer and offers the possibility of developing novel approaches to targeting tumor dependence on altered metabolic pathways for effective therapeutic interventions.
The focus of this Special Conference is to bring together
outstanding basic, translational, and clinical cancer researchers to discuss
their latest findings in the fields of epigenetic regulation, the metabolic
programs of tumors, cancer immunometabolism, in vivo metabolism models, stem
cells, and more. We will also discuss how these findings are being investigated
and applied to developing novel therapies for cancer treatment.
Continuing Medical Education Activity AMA PRA Category 1 CreditsTM available